JP2022009125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022009125A5 JP2022009125A5 JP2021168488A JP2021168488A JP2022009125A5 JP 2022009125 A5 JP2022009125 A5 JP 2022009125A5 JP 2021168488 A JP2021168488 A JP 2021168488A JP 2021168488 A JP2021168488 A JP 2021168488A JP 2022009125 A5 JP2022009125 A5 JP 2022009125A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- angiotensin
- patient
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 102000005862 Angiotensin II Human genes 0.000 claims 10
- 101800000733 Angiotensin-2 Proteins 0.000 claims 10
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 10
- 229950006323 angiotensin ii Drugs 0.000 claims 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- 229940109239 creatinine Drugs 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 230000004872 arterial blood pressure Effects 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177200A JP2024009958A (ja) | 2013-04-26 | 2023-10-13 | 腎不全を処置するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361816578P | 2013-04-26 | 2013-04-26 | |
| US61/816,578 | 2013-04-26 | ||
| JP2019000124A JP6962943B2 (ja) | 2013-04-26 | 2019-01-04 | 腎不全を処置するための組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000124A Division JP6962943B2 (ja) | 2013-04-26 | 2019-01-04 | 腎不全を処置するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177200A Division JP2024009958A (ja) | 2013-04-26 | 2023-10-13 | 腎不全を処置するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022009125A JP2022009125A (ja) | 2022-01-14 |
| JP2022009125A5 true JP2022009125A5 (enExample) | 2022-03-31 |
Family
ID=51792411
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016510807A Active JP6522584B2 (ja) | 2013-04-26 | 2014-04-25 | 腎不全を処置するための組成物及び方法 |
| JP2019000124A Active JP6962943B2 (ja) | 2013-04-26 | 2019-01-04 | 腎不全を処置するための組成物及び方法 |
| JP2021168488A Pending JP2022009125A (ja) | 2013-04-26 | 2021-10-14 | 腎不全を処置するための組成物及び方法 |
| JP2023177200A Pending JP2024009958A (ja) | 2013-04-26 | 2023-10-13 | 腎不全を処置するための組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016510807A Active JP6522584B2 (ja) | 2013-04-26 | 2014-04-25 | 腎不全を処置するための組成物及び方法 |
| JP2019000124A Active JP6962943B2 (ja) | 2013-04-26 | 2019-01-04 | 腎不全を処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177200A Pending JP2024009958A (ja) | 2013-04-26 | 2023-10-13 | 腎不全を処置するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9457059B2 (enExample) |
| EP (2) | EP3858437A1 (enExample) |
| JP (4) | JP6522584B2 (enExample) |
| CN (1) | CN105592855A (enExample) |
| AU (4) | AU2014256944B2 (enExample) |
| WO (1) | WO2014176534A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| AU2014256944B2 (en) * | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
| LT3607962T (lt) | 2013-12-18 | 2026-01-12 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) * | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| JP2017014206A (ja) * | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
| BR112018013847A2 (pt) | 2016-01-07 | 2018-12-18 | La Jolla Pharma Co | métodos para administrar a angiotensina ii |
| EP3235496A1 (en) * | 2016-04-19 | 2017-10-25 | Noorik Biopharmaceuticals AG | Treatment of acute renal failure |
| EP3518910A4 (en) | 2016-09-30 | 2020-11-04 | Xenamed Corporation | COMPOSITIONS OF MIDODRINE AND THEIR METHODS OF USE |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| JP7364568B2 (ja) | 2017-12-22 | 2023-10-18 | ゼナメッド コーポレーション | 持続放出ミドドリン塩酸塩組成物及び使用方法 |
| MX2020013389A (es) * | 2018-06-15 | 2021-03-31 | Ferring Bv | Composiciones de terlipresina y usos de las mismas. |
| WO2020061416A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| US20200093884A1 (en) | 2018-09-20 | 2020-03-26 | Mark C. Manning | Stable intranasal formulations of carbetocin |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| JP7694400B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694401B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694406B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694404B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694403B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694405B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
| JP7694407B2 (ja) * | 2022-01-25 | 2025-06-18 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| NO20034952D0 (no) * | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| CN101795675A (zh) * | 2006-11-17 | 2010-08-04 | 达沃尔泰拉公司 | 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 |
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| AU2011279144A1 (en) * | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
| AU2014256944B2 (en) * | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
-
2014
- 2014-04-25 AU AU2014256944A patent/AU2014256944B2/en active Active
- 2014-04-25 EP EP20207480.3A patent/EP3858437A1/en active Pending
- 2014-04-25 WO PCT/US2014/035511 patent/WO2014176534A1/en not_active Ceased
- 2014-04-25 CN CN201480036565.3A patent/CN105592855A/zh active Pending
- 2014-04-25 EP EP14788250.0A patent/EP2988770A4/en not_active Withdrawn
- 2014-04-25 JP JP2016510807A patent/JP6522584B2/ja active Active
- 2014-04-28 US US14/263,526 patent/US9457059B2/en active Active
-
2016
- 2016-09-30 US US15/282,179 patent/US20170014471A1/en not_active Abandoned
-
2019
- 2019-01-04 JP JP2019000124A patent/JP6962943B2/ja active Active
- 2019-09-27 AU AU2019236749A patent/AU2019236749B2/en active Active
-
2021
- 2021-07-30 US US17/390,165 patent/US20220193183A1/en not_active Abandoned
- 2021-10-14 JP JP2021168488A patent/JP2022009125A/ja active Pending
-
2022
- 2022-02-25 AU AU2022201290A patent/AU2022201290B2/en active Active
-
2023
- 2023-10-13 JP JP2023177200A patent/JP2024009958A/ja active Pending
-
2024
- 2024-09-12 AU AU2024219656A patent/AU2024219656A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI248816B (en) | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage | |
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2016520573A5 (enExample) | ||
| RU2018121615A (ru) | Модуляторы активности комплемента | |
| BRPI0804623A2 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| JP2023115271A5 (enExample) | ||
| Tønnesen et al. | Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction | |
| RU2005131938A (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
| Zhao et al. | Extracorporeal membrane oxygenation combined with hemoperfusion to assist in the rescue of aconitine poisoning: a case report | |
| CN104307064B (zh) | 一种肢体局部给药和透析装置及其应用 | |
| CN105412118B (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| JP2023518829A5 (enExample) | ||
| WO2004103399A1 (fr) | Utilisation d'ulinastatine pour traiter le syndrome respiratoire aigu et composition pharmaceutique contenant ulinastatine | |
| JP7312340B2 (ja) | 水素を含む加齢黄斑変性治療用組成物 | |
| WO2023064925A8 (en) | Treatment of kidney disease | |
| Houser et al. | Prolonged doxapram infusion in obesity-hypoventilation syndrome | |
| US20230270724A1 (en) | PDE3 inhibitors for treating viral infections | |
| Kandil et al. | Anaphylaxis to thymoglobulin: a case report and literature review | |
| JPWO2020166557A5 (enExample) | ||
| RU2779951C2 (ru) | Лечебные дыхательные смеси газов для поддержания жизнеспособности раненых с большой кровопотерей в условиях переохлаждения и способ их применения | |
| McNamara et al. | Doxapram reversal of respiratory failure in a patient refusing assisted ventilation | |
| RU2406539C2 (ru) | Способ лечения хронической почечной недостаточности | |
| CN100431532C (zh) | 一种由灯盏花素和冰片组成的复方注射制剂及其制备方法 | |
| RU2143264C1 (ru) | Способ лечения трахеитов | |
| WO2025104696A1 (en) | Pharmaceutical composition comprising edaravone for use in reducing levels of il-6 and tnf-alpha inflammatory markers and reducing time to withdrawal of oxygen therapy in patients with infectious diseases |